GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inter Pharma PCL (BKK:IP) » Definitions » Price-to-Owner-Earnings

Inter Pharma PCL (BKK:IP) Price-to-Owner-Earnings : 108.67 (As of May. 20, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Inter Pharma PCL Price-to-Owner-Earnings?

As of today (2025-05-20), Inter Pharma PCL's share price is ฿3.26. Inter Pharma PCL's Owner Earnings per Share (TTM) ended in Dec. 2024 was ฿0.03. It's Price-to-Owner-Earnings for today is 108.67.


The historical rank and industry rank for Inter Pharma PCL's Price-to-Owner-Earnings or its related term are showing as below:

BKK:IP' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 44.44   Med: 93.32   Max: 365.38
Current: 94.71

During the past 8 years, the highest Price-to-Owner-Earnings of Inter Pharma PCL was 365.38. The lowest was 44.44. And the median was 93.32.


BKK:IP's Price-to-Owner-Earnings is ranked worse than
83.24% of 173 companies
in the Biotechnology industry
Industry Median: 29.17 vs BKK:IP: 94.71

As of today (2025-05-20), Inter Pharma PCL's share price is ฿3.26. Inter Pharma PCL's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was ฿0.06. Therefore, Inter Pharma PCL's PE Ratio (TTM) for today is 52.58.

As of today (2025-05-20), Inter Pharma PCL's share price is ฿3.26. Inter Pharma PCL's EPS without NRI for the trailing twelve months (TTM) ended in was ฿0.06. Therefore, Inter Pharma PCL's PE Ratio without NRI for today is 52.58.

During the past 8 years, Inter Pharma PCL's highest PE Ratio without NRI was 235.79. The lowest was 18.40. And the median was 49.64.


Inter Pharma PCL Price-to-Owner-Earnings Historical Data

The historical data trend for Inter Pharma PCL's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inter Pharma PCL Price-to-Owner-Earnings Chart

Inter Pharma PCL Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - 149.31 346.15 94.71

Inter Pharma PCL Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 346.15 - 114.76 68.61 94.71

Competitive Comparison of Inter Pharma PCL's Price-to-Owner-Earnings

For the Biotechnology subindustry, Inter Pharma PCL's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inter Pharma PCL's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inter Pharma PCL's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Inter Pharma PCL's Price-to-Owner-Earnings falls into.


;
;

Inter Pharma PCL Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Inter Pharma PCL's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=3.26/0.03
=108.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inter Pharma PCL  (BKK:IP) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Inter Pharma PCL Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Inter Pharma PCL's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Inter Pharma PCL Business Description

Traded in Other Exchanges
N/A
Address
Silom Road, 140/9 ITF Tower 9th Floor, Suriyawongse, Bangrak, Bangkok, THA, 10500
Inter Pharma PCL is a biopharmaceutical company. It is engaged in the import, manufacture and distribution of drug, and dietary supplement products for humans and animals. It offers products related to Wellness and Anti-aging, Aesthetics, Diagnostics, Vitamins, and other products. The company operates in three reportable segments Human healthcare, Animal Healthcare, and Hospital and clinics in Thailand. Key revenue is derived from the Human healthcare segment.